Ellen Blanc

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

Sylvie Négrier, Gwénaëlle Gravis, David Pérol et al. · The Lancet Oncology · 2011 · 236 citations

Urology, Genitourinary Cancer, Medicine +5

A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases

Christine Chevreau, Alain Ravaud, Bernard Escudier et al. · Clinical Genitourinary Cancer · 2013 · 79 citations

Urology, Oncology, Phase Ii Trial +7

Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial

Sylvie Négrier, Céline Ferlay, Marine Gross‐Goupil et al. · European Journal of Cancer · 2020 · 58 citations · Full text

Urology, Genitourinary Cancer, Medicine +3

Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial.

B. Escudier, Sylvie Négrier, Gwénaëlle Gravis et al. · Journal of Clinical Oncology · 2010 · 52 citations

Urology, Surgical Oncology, Genitourinary Cancer +15

The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma

Helena Polena, Julie Creuzet, Maeva Dufies et al. · British Journal of Cancer · 2018 · 31 citations · Full text